Darnitsa Pharmaceutical Company Allocated More Than UAH 7.1 Mln. for Charity15 July 2020
Darnitsa Pharmaceutical Company continues supporting medical professionals and healthcare facilities and providing assistance with medicines to the population in crisis situations. For the last four months of the year 2020 Darnitsa has allocated more than UAH 7.1 mln. for purchasing lung ventilators, equipment for the primary detection of the coronavirus infection and medicines for healthcare facilities and charitable organizations.
In July three Avea lung ventilators (Vyaire Medical Inc., USA) arrived to Ukraine, which will soon commence their operation at Oleksandrivska Hospital, Kyiv City Clinical Hospital №4 and Kyiv City Clinical Hospital №9. The equipment is designed to provide artificial lung ventilation to patients in severe and critical conditions.
In total, as part of the fight against the COVID pandemic, Darnitsa together with the Zagoriy Foundation purchased six lung ventilators. This is American equipment that meets the highest standards of patient care and it will remain in healthcare facilities after the end of the pandemic.
Within the framework of the ongoing program of helping with medicines, Darnitsa provided patients of the Institute of Pediatrics, Obstetrics and Gynecology of the National Academy of Medical Sciences of Ukraine and the Western Ukrainian Specialized Children's Medical Center with medicinal products for the treatment of chronic systemic connective tissue diseases in need of maintenance therapy. The company also responded to the initiative of the Red Cross Society and donated medicines to those who suffered from the flood in Prykarpattia, and families with foster children, who are cared for by the SOS Children's Villages Ukraine Charitable Foundation.
Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group: “As a responsible business, Darnitsa shares the challenges faced by the society. That is why we systematically help the medical sector and patients in the most difficult situations. Over the past four months, we have provided assistance in the amount of UAH 7.1 million, namely equipment for anesthesia and resuscitation and medicines for those who suffered from the natural disaster in Prykarpattia. We also donated medicines for children with chronic systemic connective tissue diseases who need maintenance therapy and are treated at the Institute of Pediatrics, Obstetrics and Gynecology of the National Academy of Medical Sciences of Ukraine and the Western Ukrainian Specialized Children's Medical Center.”
Yevheniia Mazurenko, Director of the Zagoriy Foundation: “The COVID-19 virus pandemic has become a challenge for the medical system. We have previously collected feedback from medical professionals and selected the best equipment for mechanical ventilation, which will help to save the lives of patients not only during the epidemic, but also after overcoming it. The mission of the Zagoriy Foundation is to develop the culture of charity. But regardless of the mission, the funds should respond to the urgent needs of the society. Mitigating the effects of the epidemic is one such challenges.”
Darnitsa and the Zagoriy Foundation initiate the purchase of equipment for the capital's hospitals for the second time. In the spring, three lung ventilators were given to the Kyiv City Clinical Emergency Care Hospital, and an express analyzer was purchased for the Kyiv City Clinical Hospital № 4 for the initial detection of the coronavirus infection.
Darnitsa Pharmaceutical Company has been a leader in Ukraine in terms of sales of medicinal products by volume since 1998. According to the results of the year 2019, the share of Darnitsa was 13.76%. In 2019 the company increased the net income from sales by 10.3% and the net profit by 30%.
The enterprise has 14 production lines certified according to the GMP standard.
The company’s portfolio includes 280 finished medicinal products. The strategic areas include cardiology, neurology and pain management. Darnitsa’s products are exported to 16 countries of the world. The beneficiaries of Darnitsa Pharmaceutical Company is the Zagoriy family.
The Zagoriy Foundation was established in 2015 by Glib, Kateryna and Volodymyr Zagoriy. The Zagoriy Foundation systemically implements the experience of philanthropy accumulated by generations of the Zagoriy family - which makes it possible to make an impressive contribution to the development of Ukraine.
The priority area of the Fund’s activity is the development of the culture of charity. In this area the Fund systemically implements sustainable projects and certain activities.